Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
138.90
+10.41 (8.10%)
Nov 20, 2024, 4:00 PM EST - Market closed
Repligen Employees
Repligen had 1,783 employees as of December 31, 2023. The number of employees decreased by 242 or -11.95% compared to the previous year.
Employees
1,783
Change (1Y)
-242
Growth (1Y)
-11.95%
Revenue / Employee
$355,307
Profits / Employee
-$4,540
Market Cap
7.78B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,783 | -242 | -11.95% |
Dec 31, 2022 | 2,025 | 173 | 9.34% |
Dec 31, 2021 | 1,852 | 724 | 64.18% |
Dec 31, 2020 | 1,128 | 367 | 48.23% |
Dec 31, 2019 | 761 | 213 | 38.87% |
Dec 31, 2018 | 548 | 72 | 15.13% |
Dec 31, 2017 | 476 | 240 | 101.69% |
Dec 31, 2016 | 236 | 68 | 40.48% |
Dec 31, 2015 | 168 | 32 | 23.53% |
Dec 31, 2014 | 136 | 20 | 17.24% |
Dec 31, 2013 | 116 | -4 | -3.33% |
Dec 31, 2012 | 120 | -17 | -12.41% |
Dec 31, 2011 | 137 | 69 | 101.47% |
May 6, 2010 | 68 | -1 | -1.45% |
May 31, 2009 | 69 | 13 | 23.21% |
May 27, 2008 | 56 | 11 | 24.44% |
Jun 30, 2007 | 45 | 2 | 4.65% |
Jun 6, 2006 | 43 | 6 | 16.22% |
Jun 7, 2005 | 37 | -3 | -7.50% |
Jun 7, 2004 | 40 | -4 | -9.09% |
May 15, 2003 | 44 | 5 | 12.82% |
May 15, 2002 | 39 | -1 | -2.50% |
May 15, 2001 | 40 | 13 | 48.15% |
May 15, 2000 | 27 | 3 | 12.50% |
May 15, 1999 | 24 | 0 | - |
May 29, 1998 | 24 | 4 | 20.00% |
May 15, 1997 | 20 | 5 | 33.33% |
Jun 14, 1996 | 15 | -89 | -85.58% |
Mar 31, 1995 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Grifols | 23,737 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Bruker | 9,707 |
Jazz Pharmaceuticals | 2,800 |
Legend Biotech | 1,826 |
Ascendis Pharma | 879 |
RGEN News
- 8 days ago - Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth - Benzinga
- 9 days ago - Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects - Seeking Alpha
- 16 days ago - Repligen Corporation to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More - GlobeNewsWire
- 2 months ago - Repligen Opens Training & Innovation Center to Elevate Customer Experience - GlobeNewsWire
- 3 months ago - Repligen Corporation to Present at Wells Fargo Healthcare Conference - GlobeNewsWire
- 3 months ago - Exclusive: Repligen in bid for reagent vendor Maravai, sources say - Reuters